Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry

Abstract Purpose Patient-reported outcomes (PROs) have been incorporated into clinical trials for many symptoms and medical conditions. A transition from paper-based capture of PROs to electronic PROs (ePROs) has recently started. This study reports on the feasibility of ePRO assessment in a prospective registry including molecular data for patients with advanced breast cancer. Methods As part of the PRAEGNANT network, patients were invited by clinical trial staff, physicians, and nurses to complete three standardized Internet-based questionnaires (EQ 5D 5 L, CES-D and IPAQ). Feasibility was assessed by the staff members who assigned the user accounts by the patients. The completeness of the questionnaires was also assessed. Results Fifteen of 17 patients who were asked agreed to participate to complete the PRO questionnaires (EQ-5D-5L and CES-D). However, the IPAQ (physical activity) questionnaire was only validly completed by 9 patients. Feasibility was ranked better by the physicians and dedicated clinical trial staff than by the nursing staff. Conclusions Incorporating ePRO questionnaires into an advanced breast cancer registry is feasible, and no major hurdles were reported. Involving stakeholders from the start, the application is tailored to the capacities and abilities of both patients and clinical staff. The patientsʼ compliance was better with some questionnaires, but others may present difficulties.

[1]  A. Lucia,et al.  Validity of the Physical Activity Questionnaires IPAQ-SF and GPAQ for Cancer Survivors: Insights from a Spanish Cohort , 2016, International Journal of Sports Medicine.

[2]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[3]  M. Lux,et al.  Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients , 2016, Breast Cancer Research and Treatment.

[4]  R. La Touche,et al.  The level of physical activity affects the health of older adults despite being active , 2016, Journal of exercise rehabilitation.

[5]  E. Basch,et al.  Patient-reported outcomes in the evaluation of toxicity of anticancer treatments , 2016, Nature Reviews Clinical Oncology.

[6]  P. Fasching,et al.  Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills , 2016, Geburtshilfe und Frauenheilkunde.

[7]  N. Probst-Hensch,et al.  Associations between domains of physical activity, sitting time, and different measures of overweight and obesity , 2016, Preventive medicine reports.

[8]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[9]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[10]  T. Reimer,et al.  Patient-Reported Outcomes in Implant-Based Breast Reconstruction Alone or in Combination with a Titanium-Coated Polypropylene Mesh – A Detailed Analysis of the BREAST-Q and Overview of the Literature , 2015, Geburtshilfe und Frauenheilkunde.

[11]  A. Schneeweiss,et al.  Chemotherapie desmetastasiertenMammakarzinoms – ein Anachronismus in der Ära der personalisierten zielgerichteten onkologischenTherapie ? Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy ? , 2015 .

[12]  R. Plinta,et al.  The role of physical activity in preventing obesity in midlife women , 2015, Przeglad menopauzalny = Menopause review.

[13]  H Tesch,et al.  Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. , 2015, Geburtshilfe und Frauenheilkunde.

[14]  E. Basch New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. , 2014, Annual review of medicine.

[15]  Dan Li,et al.  A meta-analysis of the prevalence of depressive symptoms in Chinese older adults. , 2014, Archives of gerontology and geriatrics.

[16]  Deborah Schrag,et al.  Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Lux,et al.  Breast Cancer 2013 – Interpretation of New and Known Data , 2013 .

[18]  I. Kollak,et al.  Yoga for Patients with Early Breast Cancer and its Impact on Quality of Life - a Randomized Controlled Trial. , 2013, Geburtshilfe und Frauenheilkunde.

[19]  C. Garbe,et al.  Akzeptanz und Reliabilität eines elektronischen psychoonkologischen Screenings bei Patientinnen mit Brustkrebs: eine randomisiert-kontrollierte Studie , 2013, Psychotherapie - Psychosomatik - Medizinische Psychologie.

[20]  D. Wallwiener,et al.  [Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study]. , 2013, Psychotherapie, Psychosomatik, medizinische Psychologie.

[21]  David Cella,et al.  A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment , 2013, Supportive Care in Cancer.

[22]  K. Possinger,et al.  Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[23]  Lennart Bodin,et al.  The use of weekly text messaging over 6 months was a feasible method for monitoring the clinical course of low back pain in patients seeking chiropractic care. , 2012, Journal of clinical epidemiology.

[24]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[25]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Mechelen,et al.  Self-Administered Physical Activity Questionnaires for the Elderly , 2010, Sports medicine.

[27]  Maria Hagströmer,et al.  The International Physical Activity Questionnaire modified for the elderly: aspects of validity and feasibility , 2010, Public Health Nutrition.

[28]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[29]  E. Basch Patient-reported outcomes in drug safety evaluation. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  A. Abernethy,et al.  Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. , 2009, Journal of pain and symptom management.

[31]  David Cella,et al.  Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  David Artz,et al.  Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[34]  N. Leidy,et al.  Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  R. Willke,et al.  Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. , 2004, Controlled clinical trials.

[36]  M. Mori,et al.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.